Kiniksa Pharmaceuticals International plc (Class A) (KNSA) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (88.5% gross margin, 10% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-03, Kiniksa Pharmaceuticals International plc (Class A) (NASDAQ: KNSA) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $90.80 (-1.56% 1D, market cap $7.25B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, KNSA ranks #68 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KNSA carries a Roarable B- (71/100 RQD), trailing P/E of 129.9x, gross margin of 88.5%, and ROIC of 9.9%. By comparison, IONS (Ionis Pharmaceuticals Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -20.9%, cap $7.23B) and AMRX (Amneal Pharmaceuticals Inc.) posts a B- grade (71/100 RQD, P/E 103.2x, ROIC 14.1%, cap $7.49B). Among the 5-stock peer group, ABVX leads on earnings multiple (32.8x) while AMRX leads on capital efficiency (14.1% ROIC).
Per KNSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001730430), Kiniksa Pharmaceuticals International plc (Class A) generated $677.6M in revenue (+60.1% YoY), $59.0M in net income, and $136.4M in free cash flow against $763.6M in total assets and $88.2M in total debt. Key quantitative strengths: Strong cash generator (88.5% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±10.4% realized swing band)
SEC XBRL FY 2025 (10-K): 20.1% FCF Margin ($136.4M FCF) & 88.5% Gross Margin
Disciplined Float (+0.80% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 71/100 (B-) score, KNSA faces multiple-compression risk if 129.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Priced at 130x earnings—high expectations leave less room for a lukewarm quarter.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($80.13) or 200D SMA ($61.05) invalidates the momentum regime and cuts Target Base ($96.11) toward Bear Floor ($74.46).
Kiniksa Pharmaceuticals International plc (Class A) (KNSA) slipped -1.56% to $90.80, trading at 88% of its 52-week range ($36.56 – $98.48). High-quality cash engine (88.5% gross margin, 10% return on capital) with steady institutional support.
Yahoo Finance report covering Kiniksa Pharmaceuticals International plc (Class A) (KNSA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Kiniksa Pharmaceuticals International plc (Class A) (KNSA) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Kiniksa Pharmaceuticals International plc (Class A) (KNSA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Kiniksa Pharmaceuticals International plc (Class A) (KNSA) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Kiniksa Pharmaceuticals International plc (Class A) (KNSA) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Kiniksa Pharmaceuticals International plc (Class A) (KNSA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Kiniksa Pharmaceuticals International plc (Class A) (KNSA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Kiniksa Pharmaceuticals International plc (Class A) (KNSA) market action, institutional positioning, and fundamental catalysts.
JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $107 to $122.
The stock market saw the major indexes ultimately fall for the week as Google, Amazon, Intel and ServiceNow led a tech wreck. But many sectors thrived.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +60.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KNSA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KNSA. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Kiniksa Pharmaceuticals International plc (Class A) (KNSA) ranks #68 by composite RQD confidence (71/100, grade B-) and #131 by equity capitalization ($7.25B). Within this direct 5-issuer industry benchmark cohort, ABVX leads on earnings valuation at 32.8x trailing P/E, while AMRX leads on capital efficiency and profitability with 14.1% ROIC and 36.9% gross margin. KNSA currently leads its immediate peer cohort in composite quantitative strength at 71/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KNSA
ACTIVE
Kiniksa Pharmaceuticals International plc (Class A) | B- | 71/100 | 129.9x | 88.5% | 9.9% | -1.56% | $7.25B | Benchmark Subject |
| IONS Ionis Pharmaceuticals Inc. | E | 26/100 | — | 96.0% | -20.9% | -5.24% | $7.23B | /ions-vs-knsa → |
| AMRX Amneal Pharmaceuticals Inc. | B- | 71/100 | 103.2x | 36.9% | 14.1% | -4.97% | $7.49B | /amrx-vs-knsa → |
| ABVX Abivax SA | D+ | 54/100 | 32.8x | — | 9.9% | -1.94% | $7.56B | /abvx-vs-knsa → |
| AXSM Axsome Therapeutics Inc. | D- | 35/100 | — | — | -21.9% | -5.83% | $7.57B | /axsm-vs-knsa → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kiniksa Pharmaceuticals International plc (Class A) (KNSA) reported GAAP revenue of $677.6M (+60.1% vs. FY2024 revenue of $423.2M , and +150.7% cumulative change since FY2023) , GAAP net income of $59.0M, operating cash flow of $138.0M, and free cash flow of $136.4M (+436.8% YoY). On the balance sheet, KNSA closed FY2025 with $763.6M in total assets against $88.2M in total debt (Altman Z-Score: 24.45, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $677.6M | $59.0M | $138.0M | $136.4M | $763.6M | $88.2M |
| FY2024 (FY) | 2024-12-31 | $423.2M | -$43.2M | $25.7M | $25.4M | $580.6M | $64.0M |
| FY2023 (FY) | 2023-12-31 | $270.3M | $14.1M | $13.3M | $1.1M | $4.22B | $986.5M |
As of 2026-11-03, Kiniksa Pharmaceuticals International plc (Class A) (NASDAQ: KNSA) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $90.80 (-1.56% 1D, market cap $7.25B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, KNSA ranks #68 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KNSA carries a Roarable B- (71/100 RQD), trailing P/E of 129.9x, gross margin of 88.5%, and ROIC of 9.9%. By comparison, IONS (Ionis Pharmaceuticals Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -20.9%, cap $7.23B) and AMRX (Amneal Pharmaceuticals Inc.) posts a B- grade (71/100 RQD, P/E 103.2x, ROIC 14.1%, cap $7.49B). Among the 5-stock peer group, ABVX leads on earnings multiple (32.8x) while AMRX leads on capital efficiency (14.1% ROIC).
Per KNSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001730430), Kiniksa Pharmaceuticals International plc (Class A) generated $677.6M in revenue (+60.1% YoY), $59.0M in net income, and $136.4M in free cash flow against $763.6M in total assets and $88.2M in total debt. Key quantitative strengths: Strong cash generator (88.5% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
KNSA last traded at $90.80 (-1.56% on volume of 999,013 shares), positioning the stock +13.32% above its 50-day simple moving average ($80.13) and +48.73% above its 200-day simple moving average ($61.05). Across its 52-week range of $36.56 to $98.48, KNSA sits at the 87.6% percentile with a 14-day RSI of 59.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.4% ($81.36 to $100.24).
Kiniksa Pharmaceuticals International plc (Class A) (KNSA) earns a live Roarable RQD composite score of 71/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $90.80 (-1.56% 1D, market capitalization $7.25B).
Kiniksa Pharmaceuticals International plc (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, and market profile. Specific product lines, customer base, and revenue model are — The source data reports gross margin of 88.5% and operating margin of 11.4%.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Kiniksa Pharmaceuticals International plc (Class A) (KNSA) reported $677.6M in annual revenue (up from $423.2M in FY2024, +60.1% YoY) and $59.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($270.3M revenue, $14.1M net income) through FY2025, KNSA scaled operating cash flow to $138.0M and free cash flow to $136.4M, backed by $763.6M in total assets against $88.2M in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), KNSA carries a macro regime beta of 1.11 and gross margin of 88.5%.
Real-time company headlines, analyst actions, and sector developments for Kiniksa Pharmaceuticals International plc (Class A) (KNSA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Kiniksa Pharmaceuticals International plc (Class A) (KNSA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Kiniksa Pharmaceuticals International plc (Class A) (KNSA) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Kiniksa Pharmaceuticals International plc (Class A) (KNSA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Kiniksa Pharmaceuticals International plc (Class A) (KNSA) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Kiniksa Pharmaceuticals International plc (Class A) (KNSA) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Kiniksa Pharmaceuticals International plc (Class A) (KNSA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Kiniksa Pharmaceuticals International plc (Class A) (KNSA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Kiniksa Pharmaceuticals International plc (Class A) (KNSA) market action, institutional positioning, and fundamental catalysts.
Picked up a starter position in KNSA in my $100K Virtual Cash book at $92.24. Strong balance sheet (Piotroski 9/9, Altman Z 24.45) plus institutional accumulation (18/20 whale pillar) and FY 2025 revenue of $677.6M versus $423.2M in FY 2024.. Trading inside a $37.02–$98.48 52-week range with 1.78% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
@CreditSpread_Watch Shorting a 18/20 institutional whale-flow stock at $92.24 is dangerous when funds are rotating into Health Care.
Valuation of 129.9x TTM P/E and a 1.78% FCF yield leave little margin for error, with insider conviction scoring only 9/20.. Look at the math on KNSA: paying 129.9x trailing P/E for 9.9% ROIC and 11.4% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $81.17 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: